Medscape December 8, 2025
A new World Health Organization (WHO) guideline recommending GLP-1s for obesity treatment along with recent efforts to reduce the drugs’ costs are unlikely to change US obesity practice — but actions that change the US healthcare system might, clinicians told Medscape Medical News.
After the two recent and widely heralded events, Medscape Medical News sought feedback from specialists on the potential impacts of the new guideline and price reductions on their practices and patients. While generally appreciating that the guideline helps normalize obesity as a chronic, relapsing disease, our interviewees felt it would have little impact on prescribing the drugs and lifestyle interventions, given the constraints of the US healthcare system.
While price reductions may give more...
Today's Sponsors
Today's Sponsor